|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Lansoprazole
|
|
gptkbp:activities
|
Inhibits proton pump in gastric parietal cells
|
|
gptkbp:appointed_by
|
Oral tablet
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:2000
gptkb:United_States
|
|
gptkbp:associated_with
|
Reduced gastric acid secretion
|
|
gptkbp:brand
|
gptkb:Acip_Hex
|
|
gptkbp:can_be_used_with
|
Antibiotics for H. pylori eradication
|
|
gptkbp:class
|
Proton pump inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
Hypersensitivity to rabeprazole
|
|
gptkbp:developed_by
|
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:dosage_form
|
20 mg once daily
10-20 mg daily
|
|
gptkbp:duration
|
24 hours
Up to 12 weeks
|
|
gptkbp:established
|
H+/ K+ AT Pase
|
|
gptkbp:excretion
|
Urine
|
|
gptkbp:formulation
|
Delayed-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rabeprazole
|
|
gptkbp:influences
|
Gastric p H
|
|
gptkbp:ingredients
|
C18 H20 N3 O3 S
|
|
gptkbp:interacts_with
|
gptkb:Clopidogrel
gptkb:Methotrexate
gptkb:Warfarin
|
|
gptkbp:is_atype_of
|
A02 B C04
|
|
gptkbp:is_available_in
|
Tablets
Granules for suspension
|
|
gptkbp:is_available_on
|
Generic medication
|
|
gptkbp:is_used_for
|
gptkb:Zollinger-Ellison_syndrome
Peptic ulcer disease
Gastroesophageal reflux disease (GERD)
|
|
gptkbp:lifespan
|
1 to 2 hours
|
|
gptkbp:manager
|
Oral
|
|
gptkbp:marketed_as
|
gptkb:Acip_Hex
|
|
gptkbp:metabolism
|
Liver
|
|
gptkbp:notable_for
|
Long-term management of GERD
Prevention of NSAID-induced ulcers
Treatment of erosive esophagitis
|
|
gptkbp:premiered_on
|
1 hour
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:safety_features
|
Category B
|
|
gptkbp:side_effect
|
gptkb:Nausea
Diarrhea
Headache
Abdominal pain
Risk of Clostridium difficile infection
Risk of bone fractures
Risk of kidney disease
Risk of stomach cancer
|
|
gptkbp:storage
|
Room temperature
|
|
gptkbp:type_of
|
117976-90-6
|